Lupin launches Clobazam tablets

May 10, 2019 | Friday | News

It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older

Pharma major Lupin Limited (Lupin) announced the launch of Clobazam Tablets, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Clobazam Tablets, 10 mg and 20 mg is the generic version of Lundbeck Pharms, LLC’s Onfi® Tablets, 10 mg and 20 mg. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Clobazam Tablets, 10 mg and 20 mg, had an annual sale of approximately USD 479 million in the US (IQVIA MAT March 2019).